“
TL;DR
This preclinical porcine study tested if transdermal detection of a fluorescent tracer (MB-102) could track real-time drug clearance during continuous renal replacement therapy.
Asaio Journal · 11 authors, 5 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This preclinical porcine study tested if transdermal detection of a fluorescent tracer (MB-102) could track real-time drug clearance during continuous renal replacement therapy.
This preclinical study used a porcine model of anuric acute kidney injury to evaluate if transdermal fluorescence detection of the glomerular filtration rate tracer MB-102 could provide real-time assessment of drug clearance during continuous renal replacement therapy (CRRT). After bilateral nephrectomies, animals received intravenous MB-102 and meropenem, and CRRT was initiated with four different combinations of blood pump and effluent flow rates. The results suggest transdermal MB-102 detection could be a noninvasive, point-of-care tool to guide individualized drug dosing in patients on CRRT, pending human validation.